Insights

Gathering insights about Tempest…

Similar companies to Tempest

Tempest Tech Stack

Tempest uses 8 technology products and services including Docker, Amazon Route 53, Microsoft Excel, and more. Explore Tempest's tech stack below.

Docker
Containerization
Amazon Route 53
Domain Name Services
Microsoft Excel
Editors
SEMrush
Marketing Automation
JavaScript
Programming Languages
Swift
Programming Languages
HSTS
Security
Adobe Creative Suite
Visualisation Software

Media & News

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.
Jun 04, 2026 | www.globenewswire.com
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the entry a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 1,172,414 shares of the Company's common stock originally issued by the Company on November 26, 2025, having an original exercise price of $3.50 per share, at a reduced exercise price of $1.73 per share. The closing of the warrant exercise transaction is expected to occur on or about May 29, 2025, subject to satisfaction of customary closing conditions.
May 29, 2026 | www.globenewswire.com
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM)
May 14, 2026 | www.globenewswire.com
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, Ireland. Updates include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.
May 06, 2026 | www.globenewswire.com
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, May 6-9, 2026. Updates will include the latest data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest's other dual-targeting CAR-T pipeline programs.
Apr 29, 2026 | www.globenewswire.com
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to support initiation of potentially registrational study in Q4 2026 Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has achieved a key milestone in the development of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma (“rrMM”).
Apr 22, 2026 | www.globenewswire.com
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D.
Apr 14, 2026 | www.globenewswire.com

Tempest's Email Address Formats

Tempest uses at least 1 format(s):

Tempest Email Formats	Example	Percentage
First.Last@tempest.com	John.Doe@tempest.com	100%

Frequently Asked Questions

Where is Tempest's headquarters located?

Tempest's main headquarters is located at Northern Ireland United Kingdom. The company has employees across 5 continents, including EuropeNorth AmericaAsia.

What is Tempest's stock symbol?

Tempest is a publicly traded company; the company's stock symbol is TPST.

What is Tempest's official website and social media links?

Tempest's official website is tempest.com and has social profiles on LinkedIn.

What is Tempest's NAICS code?

Tempest's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does Tempest have currently?

As of June 2026, Tempest has approximately 49 employees across 5 continents, including EuropeNorth AmericaAsia. Key team members include Head Of Delivery And Operations: D. W.Director Of Finance And Human Resources: H. T.Director Of Engineering, Platform: A. P.. Explore Tempest's employee directory with LeadIQ.

What industry does Tempest belong to?

Tempest operates in the Technology, Information and Internet industry.

What technology does Tempest use?

Tempest's tech stack includes DockerAmazon Route 53Microsoft ExcelSEMrushJavaScriptSwiftHSTSAdobe Creative Suite.

What is Tempest's email format?

Tempest's email format typically follows the pattern of First.Last@tempest.com. Find more Tempest email formats with LeadIQ.

When was Tempest founded?

Tempest was founded in 2019.

Tempest

Q: What is Tempest's official website and social media links?

Tempest's official website is tempest.com. Tempest has social profiles on LinkedIn.

Q: How many employees does Tempest have currently?

Tempest has approximately 49 employees.

Q: What technology does Tempest use?

Tempest's tech stack includes Node.js, Google, Adobe Illustrator, SQLite, git.

Q: What is Tempest's NAICS code?

Tempest's NAICS code is 5415 (Computer Systems Design and Related Services).

Technology, Information and InternetNorthern Ireland, United Kingdom11-50 Employees

Tempest is an online privacy company focused on increasing privacy and data security for Internet users. Based in Northern Ireland, United Kingdom, it was founded in 2019 by Michael Levit and Sean Murphy and has built a portfolio that includes Tempest Search and Tempest Browser.

The company aims to broaden its product range to safeguard user safety across every online touchpoint. It operates across 10 countries and 3 continents, and it seeks to grow toward a global presence in Internet privacy.

Company Overview

Headquarters: Northern Ireland United Kingdom
Website: tempest.com
Stock Symbol: TPST
NAICS Code: 5415 - Computer Systems Design and Related Services
Founded: 2019
Employees: 11-50

Media & News

Funding & Financials

$10M$25M
Tempest's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
Tempest's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Tempest

Braze

Iterable

KAHUNA

Amplitude

Airship

CleverTap

MoEngage

UserIQ

Mixpanel

Tempest Tech Stack

Media & News

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

Tempest's Email Address Formats

Frequently Asked Questions

Where is Tempest's headquarters located?

What is Tempest's stock symbol?

What is Tempest's official website and social media links?

What is Tempest's NAICS code?

How many employees does Tempest have currently?

What industry does Tempest belong to?

What technology does Tempest use?

What is Tempest's email format?

When was Tempest founded?

Tempest

Company Overview

Media & News

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?